DexCom, Inc. (NASDAQ:DXCM) EVP Jacob Steven Leach sold 22,755 shares of DexCom stock in a transaction that occurred on Wednesday, June 9th. The shares were sold at an average price of $395.00, for a total value of $8,988,225.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
NASDAQ:DXCM opened at $398.98 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 5.22 and a current ratio of 5.70. DexCom, Inc. has a 52-week low of $305.63 and a 52-week high of $456.23. The company has a market cap of $38.58 billion, a price-to-earnings ratio of 78.23 and a beta of 0.76. The company’s fifty day moving average is $374.12.
DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 29th. The medical device company reported $0.33 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.02. DexCom had a return on equity of 17.86% and a net margin of 25.36%. The company had revenue of $505.00 million for the quarter, compared to analyst estimates of $482.67 million. On average, sell-side analysts predict that DexCom, Inc. will post 2.19 EPS for the current fiscal year.
DXCM has been the topic of a number of recent analyst reports. Wells Fargo & Company upgraded DexCom from an “underweight” rating to an “equal weight” rating and set a $380.00 price target on the stock in a report on Friday, May 28th. Citigroup lifted their price target on DexCom from $480.00 to $488.00 in a report on Friday, April 30th. Raymond James lifted their price target on DexCom from $449.00 to $466.00 and gave the stock an “outperform” rating in a report on Friday, April 30th. Morgan Stanley lifted their price target on DexCom from $402.00 to $410.00 and gave the stock an “equal weight” rating in a report on Friday, February 12th. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell lifted their price target on DexCom from $480.00 to $488.00 and gave the stock a “buy” rating in a report on Friday, April 30th. Three equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $459.35.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system.
See Also: Quiet Period Expirations
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.